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Abstract 1 
 2 
Aim 3 
Enhanced prognostic models are required to improve risk stratification of patients with 4 
esophageal cancer so treatment decisions can be optimised. The primary aim was to 5 
externally validate a published prognostic model incorporating PET image features. 6 
Transferability of the model was compared using only clinical variables. 7 
 8 
Methods 9 
This was a Transparent Reporting of a multivariate prediction model for Individual Prognosis 10 
Or Diagnosis (TRIPOD) type 3 study.  The model was validated against patients treated with 11 
neoadjuvant chemoradiotherapy according to the Neoadjuvant chemoradiotherapy plus 12 
surgery versus surgery alone for esophageal or junctional cancer (CROSS) trial regimen using 13 
pre- and post-harmonised image features.  The Kaplan-Meier method with log-rank 14 
significance tests assessed risk strata discrimination. A Cox proportional hazards model 15 
assessed model calibration.  Primary outcome was overall survival (OS). 16 
 17 
Results 18 
Between 2010 and 2015, 449 patients were included in the development (n=302), internal 19 
validation (n=101) and external validation (n=46) cohorts.  No statistically significant 20 
difference in OS between patient quartiles was demonstrated in prognostic models 21 
incorporating PET image features (X2=1.42, df=3, p=0.70) or exclusively clinical variables (age, 22 
disease stage and treatment; X2=1.19, df=3, p=0.75).  The calibration slope β of both models 23 
was not significantly different from unity (p=0.29 and 0.29, respectively).  Risk groups defined 24 
using only clinical variables suggested differences in OS, although these were not statistically 25 
significant (X2=0.71, df=2, p=0.70). 26 
 27 
Conclusion 28 
The prognostic model did not enable significant discrimination between the validation risk 29 
groups, but a second model with exclusively clinical variables suggested some transferable 30 
prognostic ability.  PET harmonisation did not significantly change the results of model 31 
validation. 32 
 33 
 34 
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 2 
LNMs lymph node metastases 
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NACRT neo-adjuvant chemoradiotherapy 
CROSS Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for 
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TRIPOD Transparent Reporting of a multivariate prediction model for Individual Prognosis 
Or Diagnosis 
GI gastrointestinal 
MDT multi-disciplinary team 
CaNISC Cancer Network Information System 
ATLAAS Automatic Tree-based Learning Algorithm for Advanced Segmentation 
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Introduction 1 
 2 
The prognosis of patients with esophageal cancer is poor with overall 5-year survival 3 
approximately 15%. [1] Esophageal cancer is the eighth most common malignancy 4 
worldwide, accounting for around 400,000 deaths each year. [2] 5 
 6 
Treatment strategies of patients with esophageal cancer are currently informed by 7 
radiological staging. Accurate staging is vital to inform clinicians of the likely prognosis of 8 
each patient and to appropriately risk stratify patients, ensuring the best individual 9 
management plan is decided upon. However, the stagnation in survival rate over recent 10 
decades suggests that staging accuracy, treatment selection and prognosis could be much 11 
improved. For example, lymph node metastases (LNMs) are one of the major prognostic 12 
indicators in esophageal cancer, but there is evidence that regional lymph node staging (N-13 
stage) is presently suboptimal. [3, 4] Therefore, enhanced staging methods are required to 14 
improve prognostication and subsequent risk stratification of patients.  15 
 16 
Esophageal cancer is typically confirmed by a small-sample biopsy taken during endoscopic 17 
examination. Despite advances in genomics, no molecular prognostic markers are currently 18 
in routine clinical use. [5]  It has been proposed that additional tumour phenotype 19 
information may be derived by quantitative analysis of Positron Emission Tomography (PET) 20 
scans. [6]  “Radiomics” broadly refers to automated, computerised and high-throughput 21 
extraction of quantitative image markers (features) from a large corpus of radiological 22 
images. [7]  Radiomics features typically include histogram metrics (e.g. mean and 23 
maximum), shape descriptors (e.g. longest axis length and compactness) and textures (e.g. 24 
continuous length of voxels with similar intensities). [8]  These features can be sensitive to 25 
differences in image parameters such as slice thickness. [9] Post-reconstruction 26 
harmonisation methods have been proposed to adjust for these differences, thus promoting 27 
standardised research between centres. [10]  28 
 29 
The primary aim of this study was to test the generalizability of a UK single-centre 30 
esophageal cancer prognostic model incorporating radiomic features [11] firstly pre-31 
harmonisation, then post-harmonisation, against a cohort of esophageal cancer patients 32 
treated exclusively with neo-adjuvant chemoradiotherapy (NACRT) according to the Dutch 33 
NACRT plus surgery versus surgery alone for oesophageal/junctional cancer (CROSS) trial 34 
regimen. [12]  A widely generalizable prognostic model incorporating radiomic features of 35 
primary tumours might offer clinicians complimentary data beyond traditional prognostic 36 
factors that will assist treatment decision making and risk stratification. [11, 13] The 37 
secondary aim was to compare prognostic models with and without PET image features 38 
between cohorts to provide further validation. 39 
 40 
Materials & Methods 41 
 42 
This study was designed as a Transparent Reporting of a multivariate prediction model for 43 
Individual Prognosis Or Diagnosis (TRIPOD) type 3 external independent validation study. 44 
[14]  A previously published prognostic model had been developed and internally validated 45 
in patients with esophageal cancer. Details of model development have been provided in 46 
Foley et al. [11] Briefly, the prognostic model had only been evaluated by same-centre 47 
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internal validation in patients managed by the South-East Wales Regional Upper 1 
Gastrointestinal (GI) Cancer Multi-Disciplinary Team (MDT), United Kingdom. A suitable 2 
independent cohort was not accessible at the time of publication. Institutional board review 3 
(IRB) approval was granted for the development of the prognostic model (REF 4 
14/WA/1208).  The prognostic model was developed as part of a larger study investigating 5 
the prognostic significance of image texture analysis in gastro-oesophageal cancer (STAGE), 6 
and from here-on will be known as the STAGE cohort. The external validation cohort 7 
comprised patients treated with the CROSS regimen in The Netherlands. IRB permission was 8 
obtained for the external validation cohort. 9 
 10 
Patient cohorts 11 
 12 
In total, 449 patients were included in the development and validation of this prognostic 13 
model. Figure 1 details the number of patients in each cohort and the reasons for exclusion 14 
of patients from the CROSS validation cohort. The largest number of patient exclusions 15 
(n=23) from the CROSS cohort were because of the pre-defined metabolic tumour volumes 16 
(MTV) adopted in Foley et al [11] and used in this current study for consistency. A sensitivity 17 
analysis of these excluded cases has been included in Appendix B. Other main reasons for 18 
patient exclusion were different calibration units (n=11) and ATLAAS segmentation failure 19 
(n=7). 20 
 21 
Primary Outcome 22 
 23 
The primary endpoint of the published prognostic model is overall survival, defined as the 24 
number of months survived after the date of diagnosis until death or last day of follow-up.  25 
Dates of death were obtained from the Cancer National Information System Cymru (CaNISC) 26 
database (Velindre NHS Trust, Wales), reported by the Office for National Statistics. Dates of 27 
death of patients in the CROSS cohort were obtained from the national registry.  In both 28 
cohorts, local researchers were not blinded to the dates of death. A uniform and 29 
standardised procedure for autosegmentation and radiomics computation was 30 
implemented at each centre to ensure consistent methodology. 31 
 32 
Tumour Segmentation 33 
 34 
Primary tumours were segmented on PET images using an automatic tree-based learning 35 
algorithm for advanced segmentation (ATLAAS). [15] The benefit of ATLAAS is that inter-36 
observer variability in contouring is eliminated. Full details regarding the use of ATLAAS in 37 
this study are provided in Foley et al. and Berthon et al. [11, 15] 38 
 39 
The following model equation (Eq. 1) was used to calculate a prognostic score for each 40 
patient.  This equation was derived using published methods. [16] 41 
 42 
Prognostic score = Stage Group*0.397 - Treatment*1.094 + Age*0.024 - log(Histogram 43 
Energy)*1.320 + log(TLG)*1.748 + Histogram Kurtosis*0.198 44 
Eq. 1 45 
 46 
External Validation 47 
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 1 
The ATLAAS code and equations to calculate each of the PET image features were shared 2 
between institutions.  The primary tumours on the PET scans of the CROSS patients were 3 
then segmented using ATLAAS and the MTVs produced were visually assessed for adequacy 4 
for quality control.  Validation was firstly performed with pre-harmonisation metrics and 5 
then repeated with post-harmonisation PET features to adjust for potential differences 6 
between scanners. Fully anonymised data was then shared between institutions. 7 
 8 
Different PET/CT scanners and protocols were used across the cohorts (Appendix A). Radiomics 9 
features are known to change significantly as a function of scanner model, image acquisition or 10 
reconstruction settings, therefore we explored using the post-reconstruction Combat harmonisation 11 
method [17] to harmonise features extracted from images acquired across different scanners. Slice 12 
thickness was chosen for harmonisation because images from one scanner had different thickness 13 
values, which resulted in 5 categories (Appendix A, Table A.1). Further details of the cohorts, 14 
treatments received, PET/CT protocols, metric equations, variation in image features and 15 
the post-reconstruction PET harmonisation Combat method [17], used to adjust for batch 16 
effects across different datasets, have been provided in Appendix A. 17 
 18 
Statistical analysis 19 
 20 
Categorical data are described as frequency (percent) and continuous variables as median 21 
(range) and differences assessed with appropriate non-parametric tests.  There was no 22 
missing data in the development cohort and cases with missing data were excluded from 23 
the validation CROSS cohort. Patient characteristics at staging were compared for each 24 
cohort. Boxplots were generated locally on each cohort to compare the distributions of the 25 
model variables. Firstly, the published model was applied to 46 suitable patients in the 26 
CROSS cohort prior to PET harmonisation. A second model validation was then performed 27 
using image features calculated post-harmonisation. Model discrimination was evaluated 28 
using the log-rank test; a p-value of <0.05 was defined as statistically significant. Model 29 
calibration followed a standard test procedure detailed in [18], and which has been 30 
previously implemented in [19].  In this study, we define model discrimination as preserved 31 
if the p-value of the calibration slope β = 1 is >0.05. Thirdly, we performed the same 32 
validation steps for a prognostic model developed on the same STAGE cohort, but 33 
exclusively using clinical variables (age at diagnosis, stage and treatment) and no imaging 34 
based variables. Statistical analysis was performed with SPSS version 23.0 (IBM, Chicago, 35 
USA) and MATLAB version 9.0 (MathWorks, Natick, MA). 36 
 37 
 38 
Results 39 
 40 
The baseline characteristics of the STAGE development, validation and CROSS cohorts are 41 
detailed in Table 1.  The median overall survival of the CROSS cohort was 25 months (95% 42 
confidence interval (CI) 23.0 to 31.4). The median overall survival of the STAGE development 43 
and validation cohorts was 16.0 months (95% CI 13.8-18.2) and 14.0 months (95% CI 10.4-44 
17.6), respectively. 45 
 46 
Boxplots were constructed to compare the values of log(TLG), log(Histogram Energy) and 47 
Histogram Kurtosis in between the STAGE and CROSS cohorts. (Fig. 2) Additional boxplots 48 
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and descriptive statistics of PET feature values pre- and post-harmonisation are included in 1 
Appendix B.  There were similar mean values and distributions of the 3 variables between 2 
STAGE and CROSS cohorts, although a greater number of outliers were observed for 3 
Histogram Kurtosis in the STAGE cohort.  This is probably due to a larger number of patients 4 
and greater range in MTV of the primary tumours included in the STAGE cohort. (Table B.1) 5 
 6 
A prognostic model containing clinical variables only was calculated from the STAGE 7 
development cohort using identical data from the original study.  Age at diagnosis (HR 8 
1.025, 95% CI 1.011-1.040, p<0.001), stage (0.337, 0.243-0.468, p<0.001) and treatment 9 
(1.462, 1.187-1.802, p<0.001) were all independently and significantly associated with 10 
overall survival.  11 
 12 
Prognostic model developed by clinical and radiomic features 13 
 14 
Pre-harmonisation 15 
 16 
Kaplan-Meier analysis did not demonstrate a significant difference in overall survival 17 
between patient quartiles in the CROSS cohort (X2=1.27, df=3, p=0.74). (Fig 3) The HRs of 18 
quartiles 2, 3 and 4 compared to quartile 1 was 0.89 (95% CI 0.29-2.75), 1.36 (95% CI 0.47-19 
3.92) and 0.78 (95% CI 0.25-2.41), respectively.  The calibration slope β of the prognostic 20 
score in the CROSS cohort was 1.09 (standard error (SE) 0.41).  β is not significantly different 21 
from 1 (p=0.84), which indicates that model discrimination is preserved. 22 
  23 
The mean overall survival for patient quartiles 1-4 were 34.0 months (95% CI 19.0-49.2), 24 
29.5 months (95% CI 19.5-39.5), 25.9 months (95% CI 14.8-37.0) and 41.2 months (95% CI 25 
25.9-56.4), respectively. Median overall survival could not be calculated for all quartiles. The 26 
median prognostic score for quartiles 1-4 was -0.51 (n=11, range -1.14 to -0.37), -0.15 27 
(n=11, range -0.36 to 0.01), 0.20 (n=11, range 0.04 to 0.30) and 0.48 (n=13, range 0.30 to 28 
1.16), respectively.   29 
 30 
Post-harmonisation 31 
 32 
Following post-reconstruction PET harmonisation, repeated Kaplan-Meier analysis did not 33 
demonstrate a significant difference in overall survival between patient quartiles in the 34 
CROSS cohort (X2=1.42, df=3, p=0.70). (Fig 3) The HRs of quartiles 2, 3 and 4 compared to 35 
quartile 1 was 0.78 (95% CI 0.24-2.55), 1.47 (95% CI 0.50-4.25) and 1.15 (95% CI 0.39-3.40), 36 
respectively.  The calibration slope β of the prognostic score in the CROSS cohort was 1.26 37 
(standard error (SE) 0.22).  β is not significantly different from 1 (p=0.29), which indicates 38 
that model discrimination is preserved. The adjusted survival data for the patient quartiles is 39 
available in Appendix B.  40 
 41 
These results indicate that PET harmonisation did not have a substantial effect on model 42 
validation, with similar results obtained using both methods. 43 
 44 
Prognostic model developed with clinical features only 45 
 46 
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The median prognostic score of the model developed with clinical variables only was -2.68 1 
(range -4.89 to -0.17).  As shown in Figure 4, Kaplan-Meier analysis did not demonstrate a 2 
significant difference in overall survival between patient quartiles in the CROSS cohort 3 
(X2=1.19, df=3, p=0.75).  The HRs of quartiles 2, 3 and 4 compared to quartile 1 was 0.93 4 
(95% CI 0.27-3.23), 1.41 (95% CI 0.45-4.43) and 1.53 (95% CI 0.51-4.57), respectively.  The 5 
calibration slope β of the prognostic score in the CROSS cohort was 2.15 (SE 0.72).  β is not 6 
significantly different from 1 (p=0.29), which indicates that model discrimination is 7 
preserved.  8 
 9 
In the prognostic model with clinical variables only, patients in quartiles 2 & 3 were 10 
combined to create an intermediate risk group, following a previously published method. 11 
[20] (Fig. 5)  Applying Bonferroni correction, there was no statistically significance difference 12 
between the low, intermediate and high risk groups (X2 0.712, df 2, p=0.701) but a 13 
separation in overall survival curves was observed (intermediate risk vs low risk HR 1.16 14 
(95% CI 0.41-3.30 and high risk vs low risk HR 1.53 (95% CI 0.51-4.58)).  The calibration slope 15 
β= 2.15 (SE .72, p-value 0.29) indicating model discrimination was preserved. 16 
 17 
Discussion 18 
 19 
Patients with esophageal cancer have a poor prognosis and the incidence of the disease is 20 
increasing. [21] Despite advances in modern healthcare, survival rates remain low. 21 
Enhanced staging algorithms are required to improve the accuracy of staging, which informs 22 
clinicians of the likely prognosis and provides subsequent patient risk stratification. 23 
Prognostic models incorporating radiomic features are one strategy being investigated for 24 
this purpose.   25 
 26 
This external validation study has shown that results of a developed prognostic model 27 
combining clinical risk factors and PET radiomics features was not replicated in a cohort of 28 
patients treated with the CROSS trial regimen.  However, when a prognostic model including 29 
only clinical variables from the STAGE development cohort was tested, some aspects of the 30 
model were indicative of transferability to the CROSS cohort.  Our data shows that clinical 31 
features of esophageal cancer remain prognostic across different countries and studies. 32 
 33 
Despite not being able to replicate the validation results of the published prognostic model, 34 
this study remains clinically important because more accurate staging of esophageal cancer 35 
is essential to improve survival rates. Validated prognostic and predictive radiomics models 36 
are one strategy to improve radiological staging of esophageal cancer. [22] Greater staging 37 
accuracy will improve patient risk stratification, which is critically important for optimising 38 
personalised treatment decision-making. Once validated, staging algorithms incorporating 39 
radiomics may enable clinicians to decide upon the best management plan from the outset 40 
of diagnosis, therefore providing the greatest chance of survival for each patient.   41 
 42 
A number of important methodological reasons in the modelling process may have 43 
contributed to the lack of external validity of the prognostic model when transported to the 44 
CROSS observations.  First, the PET image acquisition protocols in the CROSS regimen cohort 45 
may not have been as strictly policed as in the STAGE study, leading to divergence in PET 46 
acquisition parameters. (Table A.1)  All patients in STAGE (n=403) were staged using the 47 
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same PET/CT scanner and protocol. However, different PET/CT scanners and protocols were used 1 
in both the STAGE and CROSS cohorts. Harmonising PET image features demonstrated little 2 
improvement in the model validity between cohorts. 3 
 4 
Harmonising PET image features demonstrated little improvement in the model validity 5 
between cohorts, which supports this post-reconstruction method in external validation 6 
radiomics studies and suggests that harmonisation had little influence in these cohorts. 7 
These findings contradict those of Orlhac et al. [10] Several factors could explain the lack of 8 
effect. The clinical variables of patient age, TNM stage and treatment are likely to have the 9 
greatest impact on overall survival compared to the image features. The PET features used 10 
in the original model by Foley et al (TLG, Histogram Energy and Histogram Kurtosis) were 11 
not investigated in Orlhac et al. Furthermore, although the Combat algorithm has been used 12 
in genomics, it has not yet been validated in radiomics. A consensus on uniformly 13 
standardised PET imaging protocols is required for multi-institutional validation of 14 
prognostic/predictive models incorporating radiomics. [23] 15 
 16 
Second, the prognostic model excluded patients with small MTV < 5 mL, thus further 17 
reducing the number of CROSS patients that were eligible for validation.  The small patient 18 
numbers in the external validation cohort limits the ability to replicate the results of the 19 
STAGE prognostic model. This study is likely to be under-powered and improved validation 20 
could be achieved by increasing the cohort size.  Patients with a smaller MTV were more 21 
likely to be suitable for radical therapy and therefore eligible for recruitment into the CROSS 22 
trial. When the excluded small MTV cases were tested in the sensitivity analysis included in 23 
Appendix B, no significant difference in overall survival between patient quartiles remained 24 
(X2=3.85, df=3, p=0.28). In addition, evidence at the time of prognostic model development 25 
suggested possible unstable segmentation at smaller MTVs and an increase in redundant 26 
(highly cross-correlated) radiomic data that can be extracted. [24]  There is no clear 27 
consensus on minimum MTV in PET radiomics studies.  One study recommends excluding 28 
MTVs of < 45 mL, although only one calculation choice for local entropy, despite the many 29 
possibilities of discretisation steps and matrices available, was evaluated in this study. [25] 30 
Other studies have previously recommend excluding patients with a primary MTV of < 10 31 
mL. [26, 27] However, prognostic models including image features extracted from small 32 
tumour volumes can still be developed. [8] The original model by Foley et al. did not 33 
examine a wide range of higher order features, some of which may have turned out 34 
reproducible and significantly prognostic with the expanded dataset. However, since the 35 
scope of this study was only the feasible generalizability of the original model, we did not 36 
re-analyse using additional textural features. The possibility for including redundant data 37 
exists but providing the study is appropriately powered, the model can still be compared to 38 
those containing only clinical variables. 39 
 40 
Third, the development of the previous prognostic model did not include an exhaustive 41 
radiomic feature selection steps to identify features that would be robustly reproducible 42 
within the STAGE cohort and hence more likely to be transferable to the CROSS cohort. [8]  43 
Details of the PET variables implemented in the developed prognostic model can be found 44 
in Foley et al. [11]  These variables were shown to have prognostic significance in the early 45 
radiomics literature [28-30] and were implemented identically. 46 
 47 
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More studies are required to test the reliability, robustness and additional value of PET 1 
image features across a range of MTVs and between different PET/CT scanners. [9, 26]  2 
Regarding the original model, TLG and Histogram Energy have shown good reproducibility 3 
results, however there is mixed evidence for Histogram Kurtosis. [31]  Previous studies have 4 
found significant associations between higher order features and overall survival [29] and 5 
that the amount of complementary radiomic information gained increases with larger 6 
MTVs. [26] Despite this, the original development study did not demonstrate prognostic 7 
significance of any higher order features, although only 3 such features were investigated.  8 
 9 
Advanced correction algorithms are being developed to harmonise features extracted from 10 
scans with different acquisition parameters, which could greatly benefit multi-centre 11 
radiomic studies and reduce variation in metrics. [32]   12 
 13 
Standardisation efforts such as the Image Biomarker Standardisation Initiative (IBSI) [33] are 14 
an important methodological step towards reducing sensitivity of radiomic features to 15 
computation (image extraction) software.  Deployment of the same autosegmentation tool 16 
(ATLAAS [15]) reduced inter-observer variability in contouring and the same feature 17 
extraction software that was executed locally was used in both participating centres.  These 18 
techniques are examples of standardised processes that improve the robustness of radiomic 19 
features. 20 
 21 
Lastly, a relatively small proportion of the STAGE cohort received NACRT or surgery alone 22 
(Table 1). These differences may not have been adjusted for completely by the original 23 
model multivariate regression.  The STAGE cohort is relatively heterogeneous cohort of 24 
patients compared to the CROSS cohort, because it was collected during an observational 25 
cohort study recruiting all patients with esophageal cancer.  Patients in the CROSS cohort 26 
were all treated with NACRT, so they share more similar characteristics. Differences 27 
between validation cohorts are important in external validation studies because the 28 
generalisation of the model can be tested at its extremes. Furthermore, this points the way 29 
forward to improved (reproducible) feature selection methodology and updating of the 30 
original model to address a more generalized clinical question. 31 
 32 
All prognostic models must be validated in an independent external cohort before being 33 
considered for use in clinical practice because many models present optimistic and over-34 
fitted results from development cohorts. [34]  However, external validation studies are 35 
rarely performed.  A review of the performance of prognostic models showed that 11% are 36 
externally validated. [35] This may explain why few developed prognostic models are 37 
adopted into clinical practice. [36]  Our collaborative research group is planning to update 38 
this prognostic model and perform a further external validation study with more robust 39 
feature selection and standardised feature extraction algorithms using all tumour volumes. 40 
 41 
In conclusion, this initial TRIPOD type 3 external validation study evaluated a prognostic 42 
model developed in esophageal cancer patients staged with PET/CT.  The prognostic model 43 
did not enable significant discrimination between patient risk groups in the CROSS cohort, 44 
but a second model including clinical variables only (age, disease stage and treatment) 45 
demonstrated transferable prognostic factors between international cohorts. 46 
  47 
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Tables 
 
Table 1. Baseline Characteristics of Patients in Development, Validation and CROSS Cohorts 
Frequency (%) STAGE Development 
Cohort (n=302) 
STAGE Validation 
Cohort (n=101) 
CROSS cohort  
(n= 46) 
p-value* 
Median Age 67.0 years  
(Range 39-83) 
69.0 years 
(Range 39-84) 
64.5 years 
(Range 47-77.8)  
0.114 
Gender (M: F)  
 
227 (75.2): 75 (24.8) 78 (77.2): 23 (22.8) 38 (82.6): 8 (17.4) 0.528 
Histology  
Adeno 
SCC 
 
237 (78.5) 
65 (21.5) 
 
79 (78.2) 
22 (21.8) 
 
39 (84.8) 
7 (15.2) 
 
0.602 
Tumour Location  
Oesophagus 
Gastro-oesophageal 
junction 
 
192 (63.6) 
110 (36.4) 
 
 
47 (46.5) 
54 (53.5) 
 
 
28 (60.9) 
18 (39.1) 
0.010 
Stage Groups 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
 
17 (5.6) 
56 (18.5) 
160 (53.1) 
69 (22.8) 
 
2 (2.0)              
24 (23.8) 
57 (56.4) 
18 (17.8) 
 
2 (4.4) 
10 (21.7) 
33 (71.7) 
1 (2.2) 
0.018 
Treatment 
Curative 
SA 
NACT 
NACRT 
dCRT 
Palliative 
 
158 (52.3) 
24 (15.2) 
67 (42.4) 
13 (8.2) 
54 (34.2) 
144 (47.7) 
 
50 (49.5) 
4 (8.0) 
23 (46.0) 
7 (14.0) 
16 (32.0) 
51 (50.5) 
 
46 (100) 
0 (0.0) 
0 (0.0) 
46 (100) 
0 (0.0) 
0 (0.0) 
<0.001 
Overall Survival  
Alive 
Dead 
 
70 (23.2) 
232 (76.8) 
 
43 (42.6) 
58 (57.4) 
 
20 (43.5%) 
26 (51.5%) 
<0.001 
SCC squamous cell carcinoma; SA surgery alone; NACT neo-adjuvant chemotherapy; NACRT neo-adjuvant 
chemoradiotherapy; dCRT definitive chemoradiotherapy; *chi-square test 
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Figure Legends 
 
Figure 1. Study flowchart describing the numbers of patients in each cohort and reasons for 
exclusions from the CROSS cohort. 
 
 
 
Figure 2. Boxplots displaying pre-harmonisation mean values and interquartile ranges of 
log(TLG), log(Histogram Energy) and Histogram Kurtosis in STAGE and CROSS cohorts. 
 
 
 
Figure 3. Cumulative survival curves of patient quartiles (Q1-4) in CROSS cohort using model 
developed with clinical and radiomic features (X2=1.27, df=3, p=0.74). 
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Figure 4. Cumulative survival curves of patient quartiles (Q1-4) in CROSS cohort using model 
developed with clinical features only (X2=1.19, df=3, p=0.75). 
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Figure 5. Cumulative survival curves of combined risk groups in CROSS cohort using model 
developed with clinical features only.  The original quartile 1 corresponds to the low-risk 
group, quartiles 2 & 3 were combined to create an intermediate risk group and quartile 4 
corresponds to the high-risk group. 
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